Valuation : Theraclion

Market Cap 56.29M 65.26M 52.95M 48.24M 90.72M 6.19B 91.21M 626M 244M 3.15B 245M 240M 10.45B P/E 2024
-2.66x
P/E 2025 -6.33x
Enterprise Value 64.15M 74.36M 60.34M 54.97M 103M 7.06B 104M 713M 278M 3.59B 279M 273M 11.9B EV / Sales 2024
22.5x
EV / Sales 2025 55.4x
Free-Float
39.01%
Yield 2024 *
-
Yield 2025 -
1 day+2.67%
1 week+21.45%
Current month+2.67%
1 month+32.53%
3 months+2.67%
6 months+23.79%
Current year+27.91%
1 week 0.62
Extreme 0.62
0.8
1 month 0.58
Extreme 0.58
0.8
Current year 0.4
Extreme 0.402
0.93
1 year 0.4
Extreme 0.402
1.25
3 years 0.14
Extreme 0.1416
1.25
5 years 0.14
Extreme 0.1416
2.22
10 years 0.14
Extreme 0.1416
6.48
Manager TitleAgeSince
Chief Executive Officer - 23/05/2023
Director of Finance/CFO - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member - 21/06/2021
Director/Board Member - 27/01/2022
Director/Board Member - 28/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
+2.67%+21.45%-8.33%+24.60% 63.68M
-2.69%-4.40%+21.87%+7.77% 228B
-3.10%-4.19%+0.54%-22.09% 150B
-2.02%-0.70%-21.98%+18.96% 133B
-0.46%-3.57%-54.43%-10.33% 70B
-0.01%-0.14%+11.56%+18.80% 52.31B
+0.43%-1.01%-17.61%-14.19% 50.59B
-2.36%-3.13%+19.31%+22.98% 43.3B
-2.12%-2.08%+34.47%+44.42% 40.74B
-3.64%-2.21%-15.72%+45.34% 34.63B
Average -1.04%+0.36%-3.03%+13.62% 80.31B
Weighted average by Cap. -1.60%-2.01%-0.32%+6.10%

Financials

2024 2025
Net sales 830K 962K 781K 711K 1.34M 91.34M 1.35M 9.23M 3.59M 46.46M 3.61M 3.54M 154M 652K 756K 613K 559K 1.05M 71.74M 1.06M 7.25M 2.82M 36.49M 2.84M 2.78M 121M
Net income -5.76M -6.67M -5.42M -4.93M -9.28M -633M -9.33M -64.02M -24.92M -322M -25.06M -24.51M -1.07B -5.69M -6.6M -5.35M -4.88M -9.17M -626M -9.22M -63.27M -24.63M -318M -24.77M -24.23M -1.06B
Net Debt 3.41M 3.95M 3.21M 2.92M 5.5M 375M 5.53M 37.93M 14.76M 191M 14.85M 14.52M 633M 7.85M 9.1M 7.39M 6.73M 12.65M 864M 12.72M 87.32M 33.99M 439M 34.18M 33.44M 1.46B
Logo Theraclion
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.
Employees
36
Date Price Change Volume
01/09/26 €0.7700 +2.67% 361,654
31/08/26 €0.7500 +12.28% 407,845
28/08/26 €0.6680 +6.71% 116,914
27/08/26 €0.6260 -2.95% 43,228
26/08/26 €0.6450 +1.74% 47,209

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALTHE Stock